Abstract:

The nasal cavity serves as the principal location for the identification of allergens and the beginning of immune responses in allergic rhinitis (AR). The administration of therapeutic drugs via the nasal route enables direct targeting of the inflamed nasal mucosa, leading to expedited start of therapeutic benefits and reduced occurrence of systemic adverse reactions. Poly-herbal nasal formulations provide the capacity to offer focused therapeutic intervention to the nasal passages, effectively targeting the underlying etiology of allergic rhinitis. Animal models, such as the model using mice challenged with ovalbumin (OVA), are extensively used in preclinical investigations to examine the effectiveness and safety of prospective therapeutic interventions. via the implementation of research in a regulated animal model, this study has the capacity to provide significant knowledge on the therapeutic capabilities of poly-herbal nasal formulations. Additionally, it aims to elucidate the underlying mechanisms via which these formulations exert their effects, as well as their influence on immunological and inflammatory responses. The examination of poly-herbal nasal formulations in a mouse model challenged with ovalbumin presents a potential avenue for the development of innovative treatment strategies for allergic rhinitis. If the formulations exhibit effectiveness in diminishing nasal symptoms, regulating the immune response, and averting histopathological alterations, it may potentially pave the way for the advancement of novel pharmaceuticals or supplementary therapeutic alternatives for allergic rhinitis (AR).

Description:

allergic rhinitis, therapeutic drugs, ovalbumin, poly-herbal nasal formulations